CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 enrolled
Drug / intervention
Dexmedetomidine +2 moredrug
Likely dose
Dexmedetomidine 0.1mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05567523
NCT05567523Phase 4Completed
CompareCT.gov

Effects of Dexmedetomidine at Different Doses on Hemodynamics and Recovery Quality in Elderly Patients Undergoing Hip Replacement Surgery Under General Anesthesia

Zhenjiang First People's Hospital·interventional·Posted Oct 5, 2022·Updated Oct 13, 2022

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine, Normal saline, and 1 other intervention for Hip Fractures and Hip Disease. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The purpose of this study is to find out appropriate dose range of dexmedetomidine to provide the elderly patients satisfactory sedation and analgesia with stable hemodynamics during perioperative period of hip replacement under general anesthesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fractures, Hip Disease
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 5, 2022
Enrollment StartJun 1, 2019
Primary CompletionFeb 28, 2022
Study CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 3.7 years ago

Interventions

Dexmedetomidinedrug

In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.

Normal salinedrug

normal saline

Midazolamdrug

midazolam